Reputable factory supply Ivabradine hydrochloride 148849-67-6 in stock with high standard
- Molecular Formula: C27H36N2O5.HCl
- Molecular Weight: 505.054
- Vapor Pressure: 1.24E-15mmHg at 25°C
- Melting Point: 193-196?C
- Boiling Point: 626.9 °C at 760 mmHg
- Flash Point: 332.9 °C
- PSA： 60.47000
- LogP: 4.04990
Ivabradine hydrochloride(Cas 148849-67-6) Usage
|
Biochem/physiol Actions |
Ivabradine is used to treat chronic heart failure. |
|
Drug interactions |
Potentially hazardous interactions with other drugs Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone and disopyramide. Antibacterials: concentration possibly increased by clarithromycin and telithromycin - avoid; increased risk of ventricular arrhythmias with erythromycin - avoid. Antifungals: concentration increased by ketoconazole - avoid; concentration increased by fluconazole - reduce initial ivabradine dose; concentration possibly increased by itraconazole - avoid. Antimalarials: increased risk of ventricular arrhythmias with mefloquine. Antipsychotics: increased risk of ventricular arrhythmias with pimozide. Antivirals: concentration possibly increased by ritonavir - avoid. Beta-blockers: increased risk of ventricular arrhythmias with sotalol. Calcium-channel blockers: concentration increased by diltiazem and verapamil - avoid. Grapefruit juice: ivabradine concentration increased. Pentamidine: increased risk of ventricular arrhythmias. St John’s wort: ivabradine concentration reduced - avoid. |
|
Metabolism |
Ivabradine is extensively metabolised by the liver and the gut by oxidation through cytochrome P450 3A4 (CYP3A4) only. The major active metabolite is N-desmethyl-ivabradine (S 18982) with an exposure about 40% of that of the parent compound. This active metabolite undergoes further metabolism by CYP3A4. Excretion of metabolites occurs to a similar extent via faeces and urine. |
|
Definition |
ChEBI: A hydrochloride obtained by combining ivabradine with one molar equivalent of hydrochloric acid. Used to treat patients with angina who have intolerance to beta blockers and/or heart failure. |
|
Brand name |
Procoralan |
InChI:InChI=1/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1
148849-67-6 Relevant articles
AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
-
, (2019/11/12)
: Disclosed herein is an improved proces...
Preparation method of high-purity ivabradine hydrochloride and intermediate thereof
-
Paragraph 0056-0062, (2019/12/02)
The invention discloses a preparation me...
(1 S) - 4, 5 - dimethoxy - 1 - [(methylamino) methyl] benzocyclobutane preparation of hydrochloride salts of method
-
, (2018/04/02)
The invention provides a preparation met...
A high-purity hydrochloric acid Ivabradine preparation method (by machine translation)
-
Paragraph 0057; 0059-0062; 0063-0069, (2018/09/11)
The invention discloses a high-purity hy...
148849-67-6 Process route
-
![3-(2-[1,3]-dioxolan-2-yl-ethyl)-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one](/upload/2026/10/7024e968257c43efba695c53669a086c_8b288118-0a44-48c0-9eef-a1cdfe7ba366.png)
-
3-(2-[1,3]-dioxolan-2-yl-ethyl)-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
-
![1-[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-N-methylmethanamine hydrochloride](/upload/2026/10/fce5cefc6c3541c7a4c854f72312c207_239c1fa3-0b1d-4022-a252-64ccbdcbf9dd.png)
-
866783-13-3
1-[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-N-methylmethanamine hydrochloride
-
-
148849-67-6,148849-68-7
ivabradine hydrochloride
| Conditions | Yield |
|---|---|
|
3-(2-[1,3]-dioxolan-2-yl-ethyl)-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one;
With
hydrogen;
palladium on activated charcoal;
In
ethanol;
at 55 ℃;
under 3750.38 Torr;
1-[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-N-methylmethanamine hydrochloride;
In
ethanol; water;
at 20 - 85 ℃;
under 22502.3 Torr;
|
85%
|
|
3-(2-[1,3]-dioxolan-2-yl-ethyl)-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one;
With
palladium on activated charcoal; hydrogen;
In
ethanol;
at 55 ℃;
under 3750.38 Torr;
Autoclave;
Large scale;
1-[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-N-methylmethanamine hydrochloride;
With
palladium on activated charcoal; hydrogen;
In
ethanol; water;
at 85 ℃;
under 22502.3 Torr;
Autoclave;
Large scale;
|
85%
|
|
3-(2-[1,3]-dioxolan-2-yl-ethyl)-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one;
With
palladium on activated charcoal; hydrogen;
In
ethanol;
at 20 - 55 ℃;
under 3750380 Torr;
Autoclave;
Inert atmosphere;
1-[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-N-methylmethanamine hydrochloride;
In
ethanol; water;
at 20 - 85 ℃;
under 63756400 Torr;
Inert atmosphere;
|
85%
|
-
![3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-(methyl)amino]propyl}-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one](/upload/2026/10/491347496199434f8c73e69b88012326_4dc9366c-9fc7-40da-88b4-1f435775aea7.png)
-
1086026-31-4
3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-(methyl)amino]propyl}-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one
-
-
148849-67-6,148849-68-7
ivabradine hydrochloride
| Conditions | Yield |
|---|---|
|
3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-(methyl)amino]propyl}-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one;
With
palladium 10% on activated carbon; hydrogen; acetic acid;
at 15 - 25 ℃;
for 23h;
With
hydrogenchloride;
In
ethyl acetate; isopropyl alcohol;
at 0 - 10 ℃;
for 1h;
|
93.5%
|
|
3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-(methyl)amino]propyl}-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one;
With
palladium 10% on activated carbon; hydrogen; ammonium formate;
In
methanol;
at 25 - 30 ℃;
With
hydrogenchloride;
In
dichloromethane;
|
78%
|
|
With
hydrogenchloride; hydrogen;
palladium 10% on activated carbon;
In
water;
at 45 ℃;
for 6h;
under 7500.75 Torr;
|
|
|
Multi-step reaction
with
2
steps
1: hydrogenchloride / acetonitrile / 20 - 25 °C
2: 5%-palladium/activated carbon; hydrogen / methanol / 18 h / 30 - 35 °C / 3000.3 - 3750.38 Torr / Autoclave
With
hydrogenchloride; 5%-palladium/activated carbon; hydrogen;
In
methanol; acetonitrile;
|
|
|
3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-(methyl)amino]propyl}-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one;
With
palladium 10% on activated carbon; hydrogen;
In
methanol;
at 25 - 30 ℃;
under 5250.53 - 6000.6 Torr;
With
hydrogenchloride;
In
dichloromethane; water;
|
24.48 g
|
148849-67-6 Upstream products
-
866783-13-3
1-[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-N-methylmethanamine hydrochloride
-
155974-00-8
ivabradine
-
35202-54-1
3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile
-
41234-23-5
(R,S)-4,5-dimethoxy-1,2-dihydrocyclobutabenzene-1-carboxylic acid
148849-67-6 Downstream products
-
155974-00-8
ivabradine
-
1462470-54-7
{2-[2-({3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-4,3,5-trien-7-yl]methyl}(methyl)-amino]propyl}amino)ethyl]-4,5-dimethoxyphenyl}acetic acid
